Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib vs Chemotherapy in First-line Advanced NSCLC with EGFR PACC or L861Q Mutations
NCT06956001Phase 3Recruiting
- Sponsor
- Allist Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started Nov 2024; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06956001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06956001.